Charles River Laboratories International
The 10-second takeaway
For the quarter ended March 31 (Q1), Charles River Laboratories International met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue was unchanged and GAAP earnings per share dropped.
Gross margins improved, operating margins grew, net margins dropped.
Charles River Laboratories International recorded revenue of $286.0 million. The 11 analysts polled by S&P Capital IQ looked for sales of $286.1 million on the same basis. GAAP reported sales were 0.0% higher than the prior-year quarter's $285.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.70. The 15 earnings estimates compiled by S&P Capital IQ predicted $0.65 per share. GAAP EPS of $0.54 for Q1 were 6.9% lower than the prior-year quarter's $0.58 per share. (The prior-year quarter included -$0.07 per share in earnings from discontinued operations.)
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 36.4%, 40 basis points better than the prior-year quarter. Operating margin was 15.3%, 30 basis points better than the prior-year quarter. Net margin was 9.2%, 180 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $289.8 million. On the bottom line, the average EPS estimate is $0.69.
Next year's average estimate for revenue is $1.16 billion. The average EPS estimate is $2.68.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Charles River Laboratories International is hold, with an average price target of $37.72.
Over the decades, small-cap stocks, like Charles River Laboratories International have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Charles River Laboratories International to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Charles River Laboratories International. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.